HILLSIDE, N.J., Aug. 30, 2007 (PRIME NEWSWIRE) -- Integrated BioPharma, Inc. (Nasdaq:INBP) announced that the Securities and Exchange Commission (SEC) has approved the Company's application to withdraw its registration statement on Form S-3, which had been declared effective by the SEC on July 11, 2007. The withdrawal of the registration statement was requested because the selling stockholders listed therein do not at this time plan to sell securities of the Company as contemplated by the registration statement. No securities were sold pursuant to the prospectus included in the registration statement.
About Integrated BioPharma, Inc. (INBP)
Integrated BioPharma presently serves the varied needs of the health care industry through its Nutraceutical business, which creates, develops, manufactures and markets health products worldwide; its Biotechnology business, which uses its patented plant-based technology to produce vaccines and therapeutic antibodies; and its Pharmaceutical business, which operates contract research and cGMP manufacturing facilities. Further information is available at www.iBioPharma.com.
Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.